(Total Views: 793)
Posted On: 05/05/2022 2:45:38 AM
Post# of 148898
TNBC article that may have been posted before:
https://www.digitaljournal.com/pr/triple-nega...lveinsight
Overview of TNBC treatment. Not much about Leron but says this:
Also lists Cytodyn fourth among key pipeline companies.
(I'm still stunned that Leron, w better safety profile and slightly better efficacy results than Trodelvy ( sacituzumab), was not given BTD.... at least yet.)
https://www.digitaljournal.com/pr/triple-nega...lveinsight
Overview of TNBC treatment. Not much about Leron but says this:
Quote:
Upcoming therapies such as Ipatasertib (Hoffmann-La Roche), Pembrolizumab (Imprime PGG; HiberCell), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn) and CFI-400945 (Treadwell Therapeutics) have the potential to create a significant positive shift in the TNBC market size during the study period.
Also lists Cytodyn fourth among key pipeline companies.
(I'm still stunned that Leron, w better safety profile and slightly better efficacy results than Trodelvy ( sacituzumab), was not given BTD.... at least yet.)
(8)
(0)Scroll down for more posts ▼
